1164500-72-4
1164500-72-4
Chemical Structure
ML 145
- CAS. Nr.: 1164500-72-4
- Formula:C24H22N2O5S2
- Molecular Weight:482.57
IUPAC Name: 2-hydroxy-4-(4-((Z)-5-((E)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)butanamido)benzoic acid
InChIKey: COFMYJWNXSFLKQ-QIROLCGISA-N
SMILES: CC(/C=C(S1)/C(N(CCCC(NC2=CC(O)=C(C(O)=O)C=C2)=O)C1=S)=O)=C\C3=CC=CC=C3
Biological Activity: ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC50/EC50=21.7 μM)[1]. ML 145 has no significant activity for GPR35 at either rodent ortholog[2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ML 145 | 96.09% | ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC50/EC50=21.7 μM). ML 145 has no significant activity for GPR35 at either rodent ortholog. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ML 145 (Standard) | ML 145 (Standard) is the analytical standard of ML 145 (HY-107536). This product is intended for research and analytical applications. ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC50/EC50=21.7 μM). ML 145 has no significant activity for GPR35 at either rodent ortholog. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
F1063-0967 (Standard) | ≥98% | F1063-0967 (Standard) is the analytical standard of F1063-0967 (HY-101510). This product is intended for research and analytical applications. F1063-0967 is a Dual-specificity phosphatase 26 (DUSP26) inhibitor with an IC50 of 11.62 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
WAY-620445 | ≥95.0% | WAY-620445 is an active molecule. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Antibacterial agent 122 | Antibacterial agent 122 (compound 15) is a thiourea derivative with anti-mycobacterial activity and low cytotoxicity. Antibacterial agent 122 can be used for tuberculosis-related studies. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PPARγ agonist 10 | PPARγ agonist 10 (compound 33g) is a PPARγ agonist, and stimulats the insulin secretion, glucose uptake and insulin Sensitivity in βTC6 Cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ZTB23(R) | ZTB23(R) is a potent and selective Mycobacterium tuberculosis zinc metalloproteinase-1 (Zmp1) inhibitor with Ki value of 0.054 μM. ZTB23(R) can be used for tuberculosis (TB) research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VHR-IN-3 | VHR-IN-3 (Compound 1) is a selective vaccinia H1-related (VHR) phosphatase inhibitor with a Ki of 0.81 μM. VHR-IN-3 mimics the phosphate group through the sulfonic acid group and competitively binds to the catalytic active center of VHR. VHR-IN-3 can be used for the research of cervical cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
WAY-300570 | 98.0% | N-(4-Chlorophenyl)-3-(4-oxo-5-(thiophen-2-ylmethylene)-2-thioxothiazolidin-3-yl)propanamide is an active molecule. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
WAY-300569 | 98.0% | N-(3-Fluorophenyl)-3-(4-oxo-5-(thiophen-2-ylmethylene)-2-thioxothiazolidin-3-yl)propanamide is an active molecule. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pin1 modulator 1 | 96.26% | Pin1 modulator 1 (compound IIb-219) is a modulator that specifically targets β-Catenin and inhibits the Wnt pathway. Pin1 modulator 1 can be used in the study of Wnt-mediated related diseases, such as cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Epalrestat (Standard) | 98.59% | Epalrestat (Standard) is the analytical standard of Epalrestat. This product is intended for research and analytical applications. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Heynen-Genel S, et al. Selective GPR35 Antagonists - Probes 1 & 2. National Center for Biotechnology Information (US); 2010-2010 Feb 28. [Content Brief]
- [2]. Laura Jenkins, et al. Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J Pharmacol Exp Ther. 2012 Dec;343(3):683-95. [Content Brief]
